BioSpace News Archive

Healthcare and employee benefits are the second highest personnel cost, surpassed only by salaries. At Demotech’s I LEAD Conference 2019 Sandy Elsass, President and Co-founder, The HealthShare Plan, will discuss the futility of attempting to control healthcare costs while addressing the power of managing healthcare costs by focusing on both the expectations and wellness of employees.

In contract extension, Medical Home Network ACO takes financial risk and redesigns care for Medicaid beneficiaries

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 2019 JMP Securities Life Sciences Conference

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company’s Chief Executive Officer, Rob Neville, and Chief Operating Officer, Taneli Jouhikainen, will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time in the Fontainebleau room, The St. Regis, New York.

PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2019.

Health Maintenance Organizations created the capitation method of payment, touted in the 1990s as the wave of the future, which would contain runaway medical costs, writes Lawrence Huntoon, M.D., Ph.D., in the summer issue of the Journal of American Physicians and Surgeons.

An international study led by scientists in Oakland, Calif., and Munich, Germany, may offer hope to children and adults with a rare and debilitating genetic disorder, Pantothenate Kinase-associated neurodegeneration (PKAN), as well as a potentially new approach to treat other neurodegenerative disorders such as Alzheimer’s, Parkinson’s disease and multiple sclerosis.

On June 12, 2019, Vice Chancellor Joseph Slights of the Court of Chancery of the State of Delaware issued an oral ruling granting the motion of Macrophage Therapeutics, Inc. (“MT”), a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), to declare as void certain transactions putatively authorized by MT’s former Chief Executive Officer

IMV Inc., a clinical stage immuno-oncology company, announced that IMV Chief Executive Officer Frederic Ors will present at the following investor conferences in June

Amgen and Allergan plc announced that the U.S. Food and Drug Administration has approved KANJINTI™ for all approved indications of the reference product, Herceptin®: for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.